Evidence map›Paper›PMID 32203205›Full record

ArticleEuropean journal of human genetics : EJHG2020

The intronic BRCA1 c.5407-25T>A variant causing partly skipping of exon 23-a likely pathogenic variant with reduced penetrance?

Hildegunn Høberg-Vetti, Elisabet Ognedal, Adrien Buisson, Tone Bøe Aaman Vamre, Sarah Ariansen, Jacqueline M Hoover, Geir Egil Eide, Gunnar Houge, Torunn Fiskerstrand, Bjørn Ivar Haukanes and 2 more

Open access · hybridAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Hildegunn Høberg-VettiWestern Norway Familial Cancer Center, Haukeland University Hospital, Bergen, Norway. hildegunn.hoberg.vetti@helse-bergen.no.ORCID http://orcid.org/0000-0002-9876-576X
Elisabet OgnedalWestern Norway Familial Cancer Center, Haukeland University Hospital, Bergen, Norway.
Adrien BuissonHospices Civils de Lyon, Lyon, France.
Tone Bøe Aaman VamreDepartment of Medical Genetics, Oslo University Hospital, Oslo, Norway.
Sarah AriansenDepartment of Medical Genetics, Oslo University Hospital, Oslo, Norway.
Jacqueline M HooverAllegheny Health Network, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0003-0624-7066
Geir Egil EideCentre for Clinical Research, Haukeland University Hospital, Bergen, Norway.
Gunnar HougeDepartment of Medical Genetics, Haukeland University Hospital, Bergen, Norway.
Torunn FiskerstrandDepartment of Medical Genetics, Haukeland University Hospital, Bergen, Norway.
Bjørn Ivar HaukanesDepartment of Medical Genetics, Haukeland University Hospital, Bergen, Norway.
Cathrine Bjorvatn *Western Norway Familial Cancer Center, Haukeland University Hospital, Bergen, Norway.
Per Morten Knappskog *Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway.
Haukeland University Hospital · NOOslo University Hospital · NOAllegheny Health Network · USHospices Civils de Lyon · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rare sequence variants in the non-coding part of the BRCA genes are often reported as variants of uncertain significance (VUS), which leave patients and doctors in a challenging position. The aim of this study was to determine the pathogenicity of the BRCA1 c.5407-25T>A variant found in 20 families from Norway, France and United States with suspected hereditary breast and ovarian cancer. This was done by combining clinical and family information with allele frequency data, and assessment of the variant's effect on mRNA splicing. Mean age at breast (n = 12) and ovarian (n = 11) cancer diagnosis in female carriers was 49.9 and 60.4 years, respectively. The mean Manchester score in the 20 families was 16.4. The allele frequency of BRCA1 c.5407-25T>A was 1/64,566 in non-Finnish Europeans (gnomAD database v2.1.1). We found the variant in 1/400 anonymous Norwegian blood donors and 0/784 in-house exomes. Sequencing of patient-derived cDNA from blood, normal breast and ovarian tissue showed that BRCA1 c.5407-25T>A leads to skipping of exon 23, resulting in frameshift and protein truncation: p.(Gly1803GlnfsTer11). Western blot analysis of transiently expressed BRCA1 proteins in HeLa cells showed a reduced amount of the truncated protein compared with wild type. Noteworthily, we found that a small amount of full-length transcript was also generated from the c.5407-25T>A allele, potentially explaining the intermediate cancer burden in families carrying this variant. In summary, our results show that BRCA1 c.5407-25T>A leads to partial skipping of exon 23, and could represent a likely pathogenic variant with reduced penetrance.

Indexed as

PenetrancePoint MutationAdultBRCA1 ProteinEconomicsFemaleGene FrequencyHeLa CellsHereditary Breast and Ovarian Cancer SyndromeHeterozygoteHumansMiddle AgedRNA SplicingBRCA1 Protein

Identifiers

PMID32203205
PMCPMC7382492
OpenAlexW3011420094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.